The District Court for the District of Delaware recently rejected Novartis’s effort to block MSN Pharmaceuticals from launching a generic version ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

While Novartis holds a diversified product portfolio, there is some product concentration with its largest drugs, Entresto (close to 15% of sales) and Cosentyx (close to 10% of sales). Both drugs will ...

Company touted Kisqali's "replacement power" as another blockbuster faces generic competition and expressed optimism about ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis could soon face generic competition for Entresto after judge's ruling.

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its blockbuster Entresto heart failure treatment.

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter ...